Preoperative chemoradiotherapy in cancer of the thoracic esophagus
| Autor: | Giuseppe Cartei, A Buffoli, Giovanni Terrosu, Fabrizio Bresadola, C Sacco, A. Iop, Carla Cedolini, E. Vigevani, S Fongione, Alessandro Uzzau, Vittorio Bresadola, Umberto Baccarani, M. Signor |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Adenocarcinoma Radiation Dosage Risk Assessment Gastroenterology Preoperative care Drug Administration Schedule Statistics Nonparametric Internal medicine Antineoplastic Combined Chemotherapy Protocols Preoperative Care Humans Medicine Prospective Studies Esophagus Aged Probability business.industry Standard treatment Cancer General Medicine Middle Aged Thorax Esophageal cancer medicine.disease Survival Analysis Surgery Esophagectomy Treatment Outcome medicine.anatomical_structure Chemotherapy Adjuvant Carcinoma Squamous Cell Female Radiotherapy Adjuvant Fluorouracil Cisplatin business Progressive disease Follow-Up Studies |
| Zdroj: | Diseases of the Esophagus. 16:9-16 |
| ISSN: | 1442-2050 1120-8694 |
| Popis: | Surgery with or without adjuvant radiotherapy (RT) is the standard treatment of esophageal cancer. Preoperative radio- and chemotherapy (CT) have been introduced to improve prognosis. We report a phase II prospective non-randomized trial of preoperative RT (42 Gy/25) plus CT (cisplatin 20 mg/mq/day plus 5-fluorouracil 600 mg/mq/day, 1-5 weeks) for the treatment of thoracic esophageal cancer. From 1993, 50 patients were enrolled (40 men and 10 women, mean age 57 years, range 30-75 years). Squamous cell carcinoma accounted for 90% of cases; 10% were adenocarcinoma. Downstaging of the disease was obtained in 77.3% of cases; there were 13 (29.5%) complete responses (CR) and 21 (47.7%) partial responses (PR). Median survival was 28 and 25 months, respectively, for CR and partial response (PR) plus stable disease (SD) and progressive disease (PD) (P = 0.05). Progressive-free median survival was 22 and 17 months, respectively, for CR and PR + SD + PD (P = 0.08). Multimodal treatment of esophageal cancer showed promising results, although not significant, in terms of survival and disease progression for patients achieving a complete pathologic response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|